Abstract

Eli Lilly & Co. has signed a deal potentially worth $1.8 billion with Tübingen, Germany-based CureVac to develop mRNA vaccines for cancer targets chosen by Lilly. In the vaccines, mRNA provides genetic instructions for making antigens, proteins that arouse and train the immune system to target cancer cells. CureVac will design, manufacture, and formulate the vaccines, and Lilly will run clinical development and commercialization. The deal includes a $50 million up-front payment and an equity investment worth about $53 million.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call